SkQ1 Suppresses the p38 MAPK Signaling Pathway Involved in Alzheimer’s Disease-Like Pathology in OXYS Rats
Open accessAbstract
Alzheimer’s disease (AD) is the most common type of dementia and is currently incurable, and mitogen-activated protein kinase (MAPK) p38 is implicated in the pathogenesis of AD. p38 MAPK inhibition is considered a promising strategy against AD, but there are no safe inhibitors capable of penetrating the blood–brain barrier. Earlier, we have shown that mitochondria-targeted antioxidant plastoquinonyl-decyltriphenylphosphonium (SkQ1) at nanomolar concentrations can prevent, slow down, or partially alleviate AD-like pathology in accelerated-senescence OXYS rats. Here we confirmed that dietary supplementation with SkQ1 during active progression of AD-like pathology in OXYS rats (aged 12–18 months) suppresses AD-like pathology progression, and for the first time, we showed that its effects are associated with suppression of p38 MAPK signaling pathway (MAPKsp) activity. Transcriptome analysis, western blotting, and immunofluorescent staining revealed that SkQ1 suppresses p38 MAPKsp activity in the hippocampus at the level of expression of genes involved in the p38 MAPKsp and reduces the phosphorylation of intermediate kinases (p38 MAPK and MK2) and a downstream protein (αB-crystallin). Thus, the anti-AD effects of SkQ1 are associated with improvement in the functioning of relevant signaling pathways and intracellular processes, thus making it a promising therapeutic agent for human AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
AD-related cognitive decline, behavioural test scores and senescence-associated myocardial disease may improve in murine models upon long-term or limited intake of SkQ1.
“Finally, AD-related cognitive decline, behavioural test scores and senescence-associated myocardial disease may improve in murine models upon long-term (lifelong) or limited (between 12 and 18 months of age) intake of SkQ1 [77,78,99,100,101].”
From The Role of Antioxidants in the Interplay between Oxidative Stress and Senescence (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The proteostasis network and its decline in ageing
Hipp, M. S., Kasturi, P., & Hartl, F. U. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0101-y · Cited by 1,642 · see citing works
An Attempt to Prevent Senescence: A Mitochondrial Approach
Skulachev, V. P., Anisimov, V. N., Antonenko, Y. N., Bakeeva, L. E., Chernyak, B. V., Erichev, V. P., Filenko, O. F., Kalinina, N. I., Kapelko, V. I., Kolosova, N. G., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.12.008 · Cited by 430 · see citing works
Self-citationLee, J. K., & Kim, N. (2017) · Molecules · doi:10.3390/molecules22081287 · Cited by 323 · see citing works
Age-related macular degeneration (AMD): Alzheimer's disease in the eye?
Kaarniranta, K., Salminen, A., Haapasalo, A., Soininen, H., & Hiltunen, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101908 · Cited by 248 · see citing works
Alzheimer’s Disease: From Firing Instability to Homeostasis Network Collapse
Frère, S. G. A., & Slutsky, I. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.028 · Cited by 230 · see citing works
Wilhelmus, M. M. M., Otte‐Höller, I., Wesseling, P., de Waal, R. M. W., Boelens, W. C., & Verbeek, M. M. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00689.x · Cited by 223 · see citing works
P38 MAP kinase is activated at early stages in Alzheimer's disease brain
Sun, A. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00180-8 · Cited by 219 · see citing works
Zhang, L., Yu, H.-M., Zhao, X., Lin, X.-F., Tan, C., Cao, G.-X., & Wang, Z.-W. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.06.021 · Cited by 215 · see citing works
Role of p38/MAPKs in Alzheimer's Disease: Implications for Amyloid Beta Toxicity Targeted Therapy
Kheiri, G., Dolatshahi, M., Rahmani, F., & Rezaei, N. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0008 · Cited by 211 · see citing works
Wei, Y., An, Z., Zou, Z., Sumpter, R., Su, M., Zang, X., Sinha, S. C., Gaestel, M., & Levine, B. (2015) · eLife · doi:10.7554/elife.05289 · Cited by 178 · see citing works
Taylor, D. M., Moser, R., Régulier, E., Breuillaud, L., Dixon, M. A., Beesen, A. A., Elliston, L., Santos, M. D. F. S., Kim, J., Jones, L., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4965-11.2013 · Cited by 116 · see citing works
Busulfan-induced senescence is dependent on ROS production upstream of the MAPK pathway
Probin, V., Wang, Y., & Zhou, D. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.020 · Cited by 105 · see citing works
Small heat shock proteins inhibit in vitro Aβ1–42 amyloidogenesis
Kudva, Y. C., Hiddinga, H. J., Butler, P. C., Mueske, C. S., & Eberhardt, N. L. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01180-0 · Cited by 102 · see citing works
Bustamante, H. A., González, A., Cerda‐Troncoso, C., Shaughnessy, R., Carola Otth, L., Soza, A., & Burgos, P. V. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00126 · Cited by 98 · see citing works
Stefanova, N. A., Kozhevnikova, O. S., Vitovtov, A. O., Maksimova, K. Y., Logvinov, S. V., Rudnitskaya, E. A., Korbolina, E. E., Muraleva, N. A., & Kolosova, N. G. (2014) · Cell Cycle · doi:10.4161/cc.28255 · Cited by 97 · see citing works
Self-citationRemoving Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Nijholt, D. A. T., Kimpe, L. D., Elfrink, H. L., Hoozemans, J. J. M., & Scheper, W. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843236 · Cited by 92 · see citing works
Lu, H., Tran, T. M. L., Park, Y., Chen, I., Lan, J., Xie, Y., & Semenza, G. L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0270 · Cited by 92 · see citing works
Björkdahl, C., Sjögren, M. J. C., Zhou, X., Concha, H., Ávila, J., Winblad, B. G., & Pei, J.-J. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21589 · Cited by 78 · see citing works
Stefanova, N. A., Muraleva, N. A., Maksimova, K. Y., Rudnitskaya, E. A., Владимировна, К. Е., Telegina, D. V., & Kolosova, N. G. (2016) · Aging · doi:10.18632/aging.101054 · Cited by 77 · see citing works
Self-citation“Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease
Rao, C. V., Asch, A. S., Carr, D. J. J., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13109 · Cited by 68 · see citing works
Stefanova, N. A., Muraleva, N. A., Korbolina, E. E., Владимировна, К. Е., Maksimova, K. Y., & Kolosova, N. G. (2014) · Oncotarget · doi:10.18632/oncotarget.2751 · Cited by 66 · see citing works
Self-citationSultan, F. A., & Sweatt, J. D. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8289-5_6 · Cited by 58 · see citing works
Kato, K., Inaguma, Y., Ito, H., et al. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00038.x · Cited by 51 · see citing works
Kolosova, N. G., Tyumentsev, M. A., Muraleva, N. A., et al. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170621111033 · Cited by 51 · see citing works
Self-citationTyumentsev, M. A., Stefanova, N. A., Muraleva, N. A., Rumyantseva, Y. V., Владимировна, К. Е., Андреевич, В. В., & Kolosova, N. G. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180065 · Cited by 51 · see citing works
Self-citationQian, F., Deng, J., Wang, G., Ye, R. D., & Christman, J. W. (2016) · Current Protein and Peptide Science · doi:10.2174/1389203716666150629121324 · Cited by 40 · see citing works
Stefanova, N. A., Ershov, N. I., & Kolosova, N. G. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3984906 · Cited by 40 · see citing works
Self-citationAssociations of Alzheimer rsquo s disease with macular degeneration
Parnetti, L. (2016) · Frontiers in Bioscience-Elite · doi:10.2741/e794 · Cited by 38 · see citing works
The Role of SKQ1 (Visomitin) in Inflammation and Wound Healing of the Ocular Surface
Wei, Y., Troger, A., Spahiu, V., Perekhvatova, N., Skulachev, M. V., Petrov, A., Chernyak, B. V., & Asbell, P. A. (2018) · Ophthalmology and Therapy · doi:10.1007/s40123-018-0158-2 · Cited by 34 · see citing works
Muraleva, N. A., Kozhevnikova, O. S., Фурсова, А. Ж., & Kolosova, N. G. (2019) · Antioxidants · doi:10.3390/antiox8060177 · Cited by 31 · see citing works
Self-citationMuraleva, N. A., Kolosova, N. G., & Stefanova, N. A. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.01.017 · Cited by 29 · see citing works
Self-citationThe MAP Kinase Phosphatase-1 MKP-1/DUSP1 Is a Regulator of Human Liver Response to Transplantation
Boutros, T., Nantel, A., Emadali, A., Tzimas, G. N., Conzen, S. D., Chevet, É., & Metrakos, P. P. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02420.x · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Role of Antioxidants in the Interplay between Oxidative Stress and Senescence
Varesi, A., Chirumbolo, S., Campagnoli, L. I. M., Pierella, E., Piccini, G. B., Carrara, A., Ricevuti, G., Scassellati, C., Bonvicini, C., & Pascale, A. (2022) · Antioxidants · doi:10.3390/antiox11071224 · Cited by 145 · see citing works
- Authors
- Muraleva, N. A., Stefanova, N. A., & Kolosova, N. G.
- Affiliations
- Institute of Cytology and Genetics (RU)
- Novosibirsk Institute of Organic Chemistry (RU)
- Corresponding author
- Muraleva, Natalia A.
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2020-07-28
- Volume
- 9
- Issue
- 8
- Pages
- 676
- ISSN
- 2076-3921 (ISSN-L)
- PMC
- PMC7463502
- OpenAlex
- W3045571752
- Cited by
- 40
- References
- 32
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 5 · 2021: 4 · 2020: 2
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antioxidants (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Higher Education of the Russian Federation (14.W03.31.0034)
- Russian Foundation for Basic Research (18-015-00336)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- SkQ1, p38 MAPK signaling, Alzheimer's disease, OXYS rats, mitochondria-targeted antioxidants, alphaB-crystallin, hippocampus, dietary supplementation, blood-brain barrier, neuroprotection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
